Literature DB >> 8625001

Preventive therapies: weighing the pros and cons.

A Laupacis.   

Abstract

The author comments on three issues raised by Dr. Kenneth G. Marshall in his series on the benefits and harms of preventive therapies, which begins in this issue on page 1493. First, because the method by which the results of clinical trials are presented markedly affects the perception of those results some measure of absolute benefit and harm must be used when the results of clinical trials are presented. Second, there is increasing interest in decision aids as a means of helping patients to understand evidence and make therapeutic choices. It is important that these aids undergo rigorous testing before they are adopted for common use. Third, evidence-based clinical practice guidelines are a welcome resource for busy clinicians. However, physicians and patients should bear in mind that interpretations of the available evidence can vary, leading to different conclusions about the appropriateness of preventive therapies.

Entities:  

Mesh:

Year:  1996        PMID: 8625001      PMCID: PMC1487816     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  15 in total

1.  The effect of a shared decisionmaking program on rates of surgery for benign prostatic hyperplasia. Pilot results.

Authors:  E H Wagner; P Barrett; M J Barry; W Barlow; F J Fowler
Journal:  Med Care       Date:  1995-08       Impact factor: 2.983

2.  Evidence based purchasing: understanding results of clinical trials and systematic reviews.

Authors:  T Fahey; S Griffiths; T J Peters
Journal:  BMJ       Date:  1995-10-21

Review 3.  Antithrombotic therapy in atrial fibrillation.

Authors:  A Laupacis; G Albers; J Dalen; M Dunn; W Feinberg; A Jacobson
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

Review 4.  Patients' health-care decision making: a framework for descriptive and experimental investigations.

Authors:  H A Llewellyn-Thomas
Journal:  Med Decis Making       Date:  1995 Apr-Jun       Impact factor: 2.583

5.  Grey zones of clinical practice: some limits to evidence-based medicine.

Authors:  C D Naylor
Journal:  Lancet       Date:  1995-04-01       Impact factor: 79.321

6.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

7.  Patient reactions to a program designed to facilitate patient participation in treatment decisions for benign prostatic hyperplasia.

Authors:  M J Barry; F J Fowler; A G Mulley; J V Henderson; J E Wennberg
Journal:  Med Care       Date:  1995-08       Impact factor: 2.983

8.  Characteristics of physicians with participatory decision-making styles.

Authors:  S H Kaplan; S Greenfield; B Gandek; W H Rogers; J E Ware
Journal:  Ann Intern Med       Date:  1996-03-01       Impact factor: 25.391

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?

Authors:  J E Hux; C D Naylor
Journal:  Med Decis Making       Date:  1995 Apr-Jun       Impact factor: 2.583

View more
  1 in total

1.  Development and Evaluation of a Decision Aid About Prenatal Testing for Women of Advanced Maternal Age.

Authors:  E R Drake; L Engler-Todd; A M O'Connor; L C Surh; A Hunter
Journal:  J Genet Couns       Date:  1999-08       Impact factor: 2.537

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.